Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1076 | 2021 |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 921 | 2022 |
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 823 | 2022 |
Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 740 | 2021 |
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 2021 | 429 | 2021 |
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ... The Lancet Public Health 6 (5), e335-e345, 2021 | 357 | 2021 |
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 296 | 2021 |
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study RK Gupta, EM Harrison, A Ho, AB Docherty, SR Knight, M van Smeden, ... The Lancet Respiratory Medicine 9 (4), 349-359, 2021 | 220 | 2021 |
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the … CI Bloom, TM Drake, AB Docherty, BJ Lipworth, SL Johnston, ... The Lancet Respiratory Medicine 9 (7), 699-711, 2021 | 168 | 2021 |
A prenylated dsRNA sensor protects against severe COVID-19 A Wickenhagen, E Sugrue, S Lytras, S Kuchi, M Noerenberg, ML Turnbull, ... Science 374 (6567), eabj3624, 2021 | 150 | 2021 |
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study TM Drake, AM Riad, CJ Fairfield, C Egan, SR Knight, R Pius, ... The Lancet 398 (10296), 223-237, 2021 | 148 | 2021 |
Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant P Elliott, D Haw, H Wang, O Eales, CE Walters, KEC Ainslie, C Atchison, ... Science 374 (6574), eabl9551, 2021 | 118 | 2021 |
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK AB Docherty, RH Mulholland, NI Lone, CP Cheyne, D De Angelis, ... The Lancet Respiratory Medicine 9 (7), 773-785, 2021 | 98 | 2021 |
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study TM Drake, CJ Fairfield, R Pius, SR Knight, L Norman, M Girvan, ... The Lancet Rheumatology 3 (7), e498-e506, 2021 | 87 | 2021 |
Recent trends and patterns in HIV‐1 transmitted drug resistance in the United Kingdom A Tostevin, E White, D Dunn, S Croxford, V Delpech, I Williams, D Asboe, ... HIV medicine 18 (3), 204-213, 2017 | 76 | 2017 |
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ... EBioMedicine 87, 2023 | 72 | 2023 |
The impact of viral mutations on recognition by SARS-CoV-2 specific T cells TI de Silva, G Liu, BB Lindsey, D Dong, SC Moore, NS Hsu, D Shah, ... Iscience 24 (11), 2021 | 63 | 2021 |
Lamivudine prophylaxis and treatment of hepatitis B virus‐exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab SE Moses, ZY Lim, M Sudhanva, S Devereux, AYL Ho, A Pagliuca, ... Journal of medical virology 78 (12), 1560-1563, 2006 | 58 | 2006 |
SARS-CoV-2 routes of transmission and recommendations for preventing acquisition: joint British infection association (BIA), healthcare infection society (HIS), infection … A Bak, MA Mugglestone, NV Ratnaraja, JA Wilson, L Rivett, SM Stoneham, ... Journal of Hospital Infection 114, 79-103, 2021 | 51 | 2021 |
Targeted case finding for hepatitis B using dry blood spot testing in the British–Chinese and South Asian populations of the North‐East of England S McPherson, M Valappil, SE Moses, G Eltringham, C Miller, K Baxter, ... Journal of Viral Hepatitis 20 (9), 638-644, 2013 | 34 | 2013 |